NAMS as reported
NewAmsterdam Pharma Company N.V. reported $23M of revenue over the trailing twelve months, −52% on the year before. 8 reported series are charted on this page, each one as filed.
$23M
Revenue, trailing twelve months · to Q1 2026 · −52% against the twelve months before
- Net Income
- −$213M
Net Income · +14% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$142M
Free Cash Flow · +1.0% year on year · trailing twelve months to Q1 2026
- Op Margin
- −56035%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $23M | −52% | Q1 2026 |
| Net Income | −$213M | +14% | Q1 2026 |
| EPS | −$1.79 | −4.8% | Q1 2026 |
| Op Margin | −56035% | n/a | Q1 2026 |
| Net Margin | −64127% | n/a | Q1 2026 |
| ROE | −28% | n/a | Q1 2026 |
| ROA | −26% | n/a | Q1 2026 |
| Free Cash Flow | −$142M | +1.0% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
NewAmsterdam Pharma Company N.V. (NAMS) - Revenue & ProfitRevenue & ProfitNewAmsterdam Pharma Company N.V. (NAMS)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com